AstraZeneca has approached rival drugmaker Gilead about a potential merger, sources say, in what would be the biggest health-care deal on record https://t.co/8ZEK0ppmHy

— Russian Market (@russian_market) June 7, 2020

アストラ ゼネカがギリアドサイエンシズに合併話を持ちかけているとの情報。Bloomberg https://t.co/AzlXbUbt4P

— 全力米国株@英語ニュース/市況/株価/貯金と給料を全力で米国株に突っ込むブログ (@komcdspxl) June 7, 2020

AstraZeneca approaches Gilead about potential merger, would be the biggest health-care deal on record https://t.co/qIJkjI6Nbi

— Ahmed Al Omran (@ahmed) June 7, 2020

Merger News: AstraZeneca Approaches Gilead Sciences - Bloomberg $gild $azn https://t.co/eXWwC9kpjm

— B I O T E C H BUYOUT AHEAD (@_B_I_O_T_E_C_H_) June 7, 2020

(Bloomberg) - AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.$AZN $GILD https://t.co/i3LVUufrFz

— Carl Quintanilla (@carlquintanilla) June 7, 2020

AstraZeneca has approached rival drugmaker Gilead about a potential merger, sources say, in what would be the biggest health-care deal on record https://t.co/BIwJmQdn7M via @business

— MANU CONSULTANTS (@manuconsultants) June 7, 2020

Extraordinary: would be the biggest healthcare deal on record if talks progress. AstraZeneca Approaches Gilead About Potential Merger https://t.co/hiLBC4VUrk

— Sabah Meddings (@sabahmeddings) June 7, 2020

The full Bloomberg story on this suggests that Gilead wasn’t/isn’t interested and there are no formal talks currently. Still, wow. https://t.co/wQcmI30qc1

— Brad Loncar (@bradloncar) June 7, 2020

CORRECTION: $AZN AstraZeneca has a market cap of £110.6B, or $140.1B. Shares are +10.8% YTD (on London Stock Exchange).$GILD Gilead has a market cap of $96.3B. Shares are +18.1% YTD, largely due to interest around remdesivir in #COVID19.https://t.co/T4rXETk5tr

— SY Investing (@syinvesting) June 7, 2020

$GILD doesnt seem interested though not too sure why $AZN is. Interest in getting a JAK1, entering cell therapy, or having recurring viral disease income? https://t.co/p4FcqMzebO

— M (@bio_clouseau) June 7, 2020

AstraZeneca Approaches Gilead About Potential Merger https://t.co/KksHujnaCN

— Acumen (@AcumenFutures) June 7, 2020

AstraZeneca Approaches Gilead About Potential Merger $AMGN $GILD https://t.co/1zAxhNhOEd

— IT-PermaBull ?? ? (@IncredibleTrade) June 7, 2020

AstraZeneca Approaches Gilead About Potential Merger; would be the biggest health-care deal ever. https://t.co/zRJ2gBz43n

— Jim Roberts (@nycjim) June 7, 2020

AstraZeneca Approaches Gilead About Potential Merger https://t.co/6KsvDYGdsJ

— LiveSquawk (@LiveSquawk) June 7, 2020

AstraZeneca Approaches Gilead About Potential Mergerhttps://t.co/0yN3RrgrtP #healthcare #chemicals #water #Biotechnology #mergers #arbitrage #MandA @ennovance https://t.co/kkOmWgSsze pic.twitter.com/24T93Mdp7w

— Mo Hossain (@MoHossain) June 7, 2020

Woah! AstraZeneca Approaches Gilead About Potential Merger! Hello, GildZeneca? https://t.co/DRBnGKoOZb

— Olexandr Isayev (@olexandr) June 7, 2020